Semaglutide versus tirzepatide is the foundational comparison of this entire drug class, and 2026 gave it a genuine update: direct head-to-head trial data, most-favored-nation pricing that changed the cost gap, and expanded indications on both sides. Here's the current state of the rematch.
| Semaglutide (Wegovy/Ozempic) | Tirzepatide (Zepbound/Mounjaro) | |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GIP + GLP-1 agonist |
| Avg. weight loss | ~15% (STEP 1) | ~22.5% top dose (SURMOUNT-1) |
| Head-to-head | SURMOUNT-5: tirzepatide produced ~47% greater relative loss vs. semaglutide | — |
| Outcomes evidence | SELECT: 20% MACE reduction, mortality benefit; kidney (FLOW), liver indications | Sleep apnea indication; heart-failure (HFpEF) data; outcomes program maturing |
| Cash price (MFN era) | $199/mo pen · oral from $149 | $299/mo pen · vials $349–$449 |
| Formats | Weekly pen, daily pill | Weekly pen, vials |
What's Genuinely New
- The head-to-head happened. SURMOUNT-5 compared the two directly in people without diabetes: tirzepatide delivered substantially greater weight loss — roughly 47% more in relative terms. The efficacy question is no longer inferred across trials; it's answered.
- Semaglutide's evidence moat widened anyway. SELECT's cardiovascular protection, FLOW's kidney benefits, and 2026's liver-disease indication give semaglutide the broadest outcomes portfolio in the class — reasons to choose it that have nothing to do with the scale.
- The price gap compressed. $199 versus $299 monthly is a $1,200/year difference — real, but nothing like the old landscape. Cost still tilts semaglutide; it no longer decides by itself.
Who Each Molecule Fits in 2026
Tirzepatide for maximum weight loss, higher starting BMIs, prior semaglutide plateaus, and comorbid sleep apnea. Semaglutide for documented cardiovascular/kidney/liver protection priorities, pill preference (tirzepatide has no oral), tighter budgets, and anyone whose target is well-served by ~15% average loss.
Sesame Care
Brand-name route — Rybelsus, oral Wegovy, and injectable brand GLP-1s via low-cost doctor visits.
Flat-rate visits · brand-name FDA-approved medications only
- FDA-approved brand-name medications only
- Fast video visits in most states
- Pairs well with $199 direct-pay channels
The Compounded Versions of This Matchup
The same comparison plays out in the compounded market at lower prices — with flat-rate programs removing tirzepatide's dose-price ladder:
Telos Rx (Tirzepatide)
Flat-rate injectable tirzepatide with zero dose-based price escalation.
Injectable compounded tirzepatide — $49 first month on 12-mo plan · $99/mo (6-mo) · $129/mo (3-mo) · $199 month-to-month, flat at any dose
- Flat pricing at every dose
- Longer commitments unlock lower rates
- Provider consult included
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.
Try Gala GLP-1 instead Paid linkGobyMeds
The lowest injectable price point we currently track.
Injectable compounded semaglutide $99/mo · tirzepatide $133/mo
- Among the lowest injectable prices tracked
- Direct pharmacy model
- Flat monthly pricing
Compounded medications are not FDA-approved. They are prepared by licensed pharmacies but have not been evaluated by the FDA for safety, effectiveness, or quality.
Visit GobyMeds Paid linkBottom Line
2026 settled the old arguments and made both drugs accessible enough that the choice is finally clinical rather than financial. Bring your priorities — not just your goal weight — to the prescriber conversation.
Last updated August 2026. Trial figures are program averages; individual results vary. Discuss selection with a licensed provider.
See the Full Comparison Grid
Every provider and channel we track — price, format, and what's included — side by side.
Compare All ProvidersMore Comparisons
Orforglipron vs. Injectable Semaglutide
Zepbound Pen vs. Vial: The Price Ladder
Best Programs for Higher Doses: Flat-Rate Rankings
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. All prescription medications discussed require evaluation by a licensed healthcare provider. Always consult your doctor before starting, stopping, or changing any medication. Individual results vary.
Affiliate Disclosure: CompareGLP-1 may earn a commission when you use links on this page, at no additional cost to you. Links marked "Paid link" are sponsored. Our comparisons are editorially independent — rankings and verdicts are never sold, and we never fabricate statistics, testimonials, or reviews.